System and method for delivering and deploying an occluding device within a vessel

Information

  • Patent Grant
  • 10322018
  • Patent Number
    10,322,018
  • Date Filed
    Monday, November 30, 2015
    8 years ago
  • Date Issued
    Tuesday, June 18, 2019
    5 years ago
Abstract
A system and method for deploying an occluding device that can be used to remodel an aneurysm within the vessel by, for example, neck reconstruction or balloon remodeling. The system comprises an introducer sheath and an assembly for carrying the occluding device. The assembly includes an elongated flexible member having an occluding device retaining member for receiving a first end of the occluding device, a proximally positioned retaining member for engaging a second end of the occluding device and a support surrounding a portion of the elongated flexible member over which the occluding device can be positioned.
Description
FIELD OF THE INVENTION

The invention generally relates to a system and method for delivering and deploying a medical device within a vessel, more particularly, it relates to a system and method for delivering and deploying an endoluminal therapeutic device within the vasculature of a patient to embolize and occlude aneurysms, particularly cerebral aneurysms.


BACKGROUND ART OF THE INVENTION

Walls of the vasculature, particularly arterial walls, may develop areas of pathological dilatation called aneurysms. As is well known, aneurysms have thin, weak walls that are prone to rupturing. Aneurysms can be the result of the vessel wall being weakened by disease, injury or a congenital abnormality. Aneurysms could be found in different parts of the body with the most common being abdominal aortic aneurysms and brain or cerebral aneurysms in the neurovasculature. When the weakened wall of an aneurysm ruptures, it can result in death, especially if it is a cerebral aneurysm that ruptures.


Aneurysms are generally treated by excluding the weakened part of the vessel from the arterial circulation. For treating a cerebral aneurysm, such reinforcement is done in many ways including: (i) surgical clipping, where a metal clip is secured around the base of the aneurysm; (ii) packing the aneurysm with small, flexible wire coils (micro-coils); (iii) using embolic materials to “fill” an aneurysm; (iv) using detachable balloons or coils to occlude the parent vessel that supplies the aneurysm; and (v) intravascular stenting.


Intravascular stents are known in the medical arts for the treatment of vascular stenoses or aneurysms. Stents are prostheses that expand radially or otherwise within a vessel or lumen to provide support against the collapse of the vessel.


In conventional methods of introducing a compressed stent into a vessel and positioning it within in an area of stenosis or an aneurysm, a guiding catheter having a distal tip is percutaneously introduced into the vascular system of a patient. The guiding catheter is advanced within the vessel until its distal tip is proximate the stenosis or aneurysm. A guidewire positioned within an inner lumen of a second, inner catheter and the inner catheter are advanced through the distal end of the guiding catheter. The guidewire is then advanced out of the distal end of the guiding catheter into the vessel until the distal portion of the guidewire carrying the compressed stent is positioned at the point of the lesion within the vessel. Once the compressed stent is located at the lesion, the stent may be released and expanded so that it supports the vessel.


SUMMARY OF THE INVENTION

Aspects of the present invention include a system and method of deploying an occluding device within a vessel. The occluding device can be used to remodel an aneurysm within the vessel by, for example, neck reconstruction or balloon remodeling. The occluding device can be used to form a barrier that retains occlusion material such as a well known coil or viscous fluids, such as “ONYX” by Microtherapeutics, within the aneurysm so that introduced material will not escape from within the aneurysm. Also, during deployment, the length of the occluding device can be adjusted in response to friction created between the occluding device and an inner surface of a catheter. When this occurs, the deployed length and circumferential size of the occluding device can be changed as desired by the physician performing the procedure.


An aspect of the present invention includes a system for supporting and deploying an occluding device. The system comprises an introducer sheath and an assembly for carrying the occluding device. The assembly includes an elongated flexible member having an occluding device retaining member for receiving a first end of the occluding device, a proximally positioned retaining member for engaging a second end of the occluding device and a support surrounding a portion of the elongated flexible member over which the occluding device can be positioned.


Another aspect of the present invention includes a system for supporting and deploying an occluding device. The system comprises an assembly for carrying the occluding device. The assembly comprises an elongated member including a flexible distal tip portion, a retaining member for receiving a first end of the occluding device, and a support surrounding a portion of the elongated flexible member for supporting the occluding device.


A further aspect of the present invention comprises a method of introducing and deploying an occluding device within a vessel. The method includes the steps of introducing an elongated sheath including an introducer sheath carrying a guidewire assembly into a catheter and advancing the guidewire assembly out of the sheath and into the catheter. The method also includes the steps of positioning an end of the catheter proximate an aneurysm, advancing a portion of the guidewire assembly out of the catheter and rotating a portion of the guidewire assembly while deploying the occluding device in the area of the aneurysm.


In another aspect an elongated flexible member supports and deploys an occluding device and the occluding device may be expanded and retracted based on input pressure. For example, air of fluid pressure may be applied to the occluding device via the flexible member to cause the occluding device to expand or retract.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 is a cross section of an occluding device delivery assembly and occluding device according to an aspect of the invention;



FIG. 2 illustrates a catheter and introducer sheath shown in FIG. 1;



FIG. 3 is a partial cut away view of the introducer sheath of FIG. 2 carrying a guidewire assembly loaded with an occluding device;



FIG. 4 is a cross section of the guidewire assembly illustrated in FIG. 3;



FIG. 5 is a schematic view of the guidewire assembly of FIG. 4;



FIG. 6 is a second schematic view of the guidewire assembly of FIG. 4;



FIG. 7 illustrates the occluding device and a portion of the guidewire assembly positioned outside the catheter, and how a proximal end of the occluding device begins to deploy within a vessel;



FIG. 8 illustrates a step in the method of deploying the occluding device;



FIG. 9 illustrates the deployment of the occluding device according to an aspect of the present invention;



FIG. 10 is a schematic view of a guidewire assembly according to another embodiment of the present invention; and



FIG. 11 is a schematic view of the deployed occluding device after having been deployed by the guidewire assembly of FIG. 10.



FIG. 12 illustrates an example of an expanded occluding device that expands responsive to pressure.



FIG. 13 illustrates the occluding device of FIG. 12 after a negative pressure is applied to the occluding device.



FIG. 14 illustrates an example of release of the distal end of the occluding device while the proximal end of the occluding device remains attached to the delivery device.



FIG. 15 illustrates an example of a partially deployed occluding device.



FIG. 16 illustrates another example of a partially deployed occluding device.



FIG. 17 illustrates the example of FIG. 16 in which the occluding device is repositioned proximally in the blood vessel.



FIG. 18 illustrates an example of an expanded occluding device.



FIG. 19 illustrates the example of FIG. 18 after the occluding device is repositioned within a blood vessel.



FIG. 20 illustrates an example of the occluding device in a retracted state.



FIG. 21 illustrates an example of repositioning the occluding device while the occluding device is retracted.





DETAILED DESCRIPTION OF THE INVENTION

An occluding device delivery assembly having portions with small cross section(s) and which is highly flexible is described herein. FIG. 1 illustrates an introducer sheath 10 according to an aspect of the present invention that receives, contains and delivers an occluding device 100 to a flexible micro-catheter 1 for positioning within the vasculature of an individual. The occluding device 100 can include those embodiments disclosed in copending U.S. Patent Application titled “Flexible Vascular Occluding Device”, U.S. Ser. No. 11/136,395, filed on May 25, 2005, which is expressly hereby incorporated by reference in its entirety.


A distal end 12 of the introducer sheath 10 is sized and configured to be received within a hub 2 of the micro-catheter 1, as shown in FIGS. 1 and 2. The hub 2 can be positioned at the proximal end of the micro-catheter 1 or at another location spaced along the length of the micro-catheter 1. The micro-catheter 1 can be any known micro-catheter that can be introduced and advanced through the vasculature of a patient. In an embodiment, the micro-catheter has an inner diameter of 0.047 inch or less. In another embodiment, the micro-catheter has an inner diameter of about 0.027 inch to about 0.021 inch. In an alternative embodiment, the micro-catheter could have an inner diameter of about 0.025 inch. However, it is contemplated that the micro-catheter 1 can have an inner diameter that is greater than 0.047 inch or less than 0.021 inch. After the introducer sheath 10 is positioned within the catheter hub 2, the occluding device 100 can be advanced from the introducer sheath 10 into the micro-catheter 1 in preparation for deploying the occluding device 100 within the vasculature of the patient.


The micro-catheter 1 may have at least one fluid introduction port 6 located adjacent the hub 2 or at another position along its length. The port 6 is preferably in fluid communication with the distal end of the micro-catheter 1 so that a fluid, e.g., saline, may be passed through the micro-catheter 1 prior to insertion into the vasculature for flushing out air or debris trapped within the micro-catheter 1 and any instruments, such as guidewires, positioned within the micro-catheter 1. The port 6 may also be used to deliver drugs or fluids within the vasculature as desired.



FIG. 3 illustrates the introducer sheath 10, an elongated flexible delivery guidewire assembly 20 that is movable within the introducer sheath 10 and the occluding device 100. As shown, the guidewire assembly 20 and the occluding device 100, carried by the guidewire assembly 20, have not been introduced into the micro-catheter 1. Instead, as illustrated, they are positioned within the introducer sheath 10. The introducer sheath 10 may be made from various thermoplastics, e.g., PTFE, FEP, HDPE, PEEK, etc., which may optionally be lined on the inner surface of the sheath or an adjacent surface with a hydrophilic material such as PVP or some other plastic coating. Additionally, either surface may be coated with various combinations of different materials, depending upon the desired results.


The introducer sheath 10 may include drainage ports or purge holes (not shown) formed into the wall near the area covering the occluding device 100. There may be a single hole or multiple holes, e.g., three holes, formed into introducer sheath 10. These purge holes allow for fluids, e.g., saline, to readily escape from in between the introducer sheath 10 and the guidewire assembly 20 when purging the sheath prior to positioning the introducer sheath 10 in contact with the catheter hub 2, e.g., to remove trapped air or debris.


As shown in FIG. 4, the guidewire assembly 20 includes an elongated flexible guidewire 21. The flexibility of the guidewire 21 allows the guidewire assembly 20 to bend and conform to the curvature of the vasculature as needed for positional movement of the occluding device 100 within the vasculature. The guidewire 21 may be made of a conventional guidewire material and have a solid cross section. Alternatively, the guidewire 21 can be formed from a hypotube. In either embodiment, the guidewire 21 has a diameter D5 ranging from about 0.010 inch to about 0.020 inch. In an embodiment, the largest diameter of the guidewire 21 is about 0.016 inch. The material used for the guidewire 21 can be any of the known guidewire materials including superelastic metals, e.g., Nitinol. Alternatively, the guidewire 21 can be formed of metals such as stainless steel. Length L4 of the guidewire can be from about 125 to about 190 cm. In an embodiment, the length L4 is about 175 cm.


The guidewire assembly 20 can have the same degree of flexion along its entire length. In an alternative embodiment, the guidewire assembly 20 can have longitudinal sections, each with differing degrees of flexion/stiffness. The different degrees of flexions for the guidewire assembly 20 can be created using different materials and/or thicknesses within different longitudinal sections of the guidewire 21. In another embodiment, the flexion of the guidewire 21 can be controlled by spaced cuts (not shown) formed within the delivery guidewire 21. These cuts can be longitudinally and/or circumferentially spaced from each other. The cuts can be formed with precision within the delivery guidewire 21. Different sections of the delivery guidewire 21 can include cuts formed with different spacing and different depths to provide these distinct sections with different amounts of flexion and stiffness. In any of the above embodiments, the guidewire assembly 20 and the guidewire 21 are responsive to torque applied to the guidewire assembly 20 by the operator. As discussed below, the torque applied to the guidewire assembly 20 via the guidewire 21 can be used to release the occluding device 100 from the guidewire assembly 20.


The size and shape of the cuts formed within the delivery guidewire 21 may be controlled so as to provide greater or lesser amounts of flexibility. Because the cuts can be varied in width without changing the depth or overall shape of the cut, the flexibility of the delivery guidewire 21 may be selectively altered without affecting the torsional strength of the delivery guidewire 21. Thus, the flexibility and torsional strength of the delivery guidewire 21 may be selectively and independently altered.


Advantageously, longitudinally adjacent pairs of cuts may be rotated about 90 degrees around the circumference of the delivery guidewire 21 from one another to provide flexure laterally and vertically. However, the cuts may be located at predetermined locations to provide preferential flexure in one or more desired directions. Of course, the cuts could be randomly formed to allow bending (flexion) equally, non-preferentially in all directions or planes. In one embodiment, this could be achieved by circumferentially spacing the cuts.


The flexible delivery guidewire 21 can include any number of sections having the same or differing degrees of flexion. For example, the flexible delivery guidewire 21 could include two or more sections. In the embodiment illustrated in FIG. 4, the flexible delivery guidewire 21 includes three sections, each having a different diameter. Each section can have a diameter of about 0.003 inch to about 0.025 inch. In an embodiment, the diameter of one or more sections can be about 0.010 inch to about 0.020 inch. A first section 22 includes a proximal end 23 that is located opposite the position of the occluding device 100. The first section 22 can have a constant thickness along its length. Alternatively, the first section 22 can have a thickness (diameter) that tapers along its entire length or only a portion of its length. In the tapered embodiment, the thickness (diameter) of the first section 22 decreases in the direction of a second, transition section 24. For those embodiments in which the guidewire 21 has a circular cross section, the thickness is the diameter of the section.


The second, transition section 24 extends between the first section 22 and a third, distal section 26. The second section 24 tapers in thickness from the large diameter of the first section 22 to the smaller diameter of the third section 26. As with the first section 22, the second section 24 can taper along its entire length or only a portion of its length.


The third section 26 has a smaller thickness compared to the other sections 22, 24 of the delivery guidewire 21. The third section 26 extends away from the tapered second section 24 that carries the occluding device 100. The third section 26 can taper along its entire length from the second section 24 to the distal end 27 of the delivery guidewire 21. Alternatively, the third section 26 can have a constant diameter or taper along only a portion of its length. In such an embodiment, the tapering portion of the third section 26 can extend from the second section 24 or a point spaced from the second section 24 to a point spaced from distal end 27 of the delivery guidewire 21. Although three sections of the delivery guidewire 21 are discussed and illustrated, the delivery guidewire 21 can include more than three sections. Additionally, each of these sections can taper in their thickness (diameter) along all or only a portion of their length. In any of the disclosed embodiments, the delivery guidewire 21 can be formed of a shape memory alloy such as Nitinol.


A tip 28 and flexible tip coil 29 are secured to the distal end 27 of the delivery guidewire 21 as shown in FIGS. 4 and 5. The tip 28 can include a continuous end cap or cover as shown in the figures, which securely receives a distal end of the tip coil 29. Flexion control is provided to the distal end portion of the delivery guidewire 21 by the tip coil 29. However, in an embodiment, the tip 28 can be free of the coil 29. The tip 28 has a non-percutaneous, atraumatic end face. In the illustrated embodiment, the tip 28 has a rounded face. In alternative embodiments, the tip 28 can have other non-percutaneous shapes that will not injure the vessel in which it is introduced. As illustrated in FIG. 4, the tip 28 includes a housing 45 that securely receives the distal end of the guidewire 21 within an opening 46 in the interior surface of the housing 45. The guidewire 21 can be secured within the opening by any known means.


As shown in FIG. 4, the tip coil 29 surrounds a portion of the guidewire 21. The tip coil 29 is flexible so that it will conform to and follow the path of a vessel within the patient as the tip 28 is advanced along the vessel and the guidewire 21 bends to follow the tortuous path of the vasculature. The tip coil 29 extends rearward from the tip 28 in the direction of the proximal end 23, as shown.


The tip 28 and coil 29 have an outer diameter D1 of about 0.010 inch to about 0.018 inch. In an embodiment, their outer diameter D1 is about 0.014 inch. The tip 28 and coil 29 also have a length L1 of about 0.1 cm to about 3.0 cm. In an embodiment, they have a total length L1 of about 1.5 cm.


A proximal end 30 of the tip coil 29 is received within a housing 32 at a distal end 24 of a protective coil 35, as shown in FIGS. 1 and 4. The housing 32 and protective coil 35 have an outer diameter D2 of about 0.018 inch to about 0.038 inch. In an embodiment, their outer diameter D2 is about 0.024 inch. The housing 32 and protective coil 35 have a length L2 of about 0.05 cm to about 0.2 cm. In an embodiment, their total length L2 is about 0.15 cm.


The housing 32 has a non-percutaneous, atraumatic shape. For example, as shown in FIG. 5, the housing 32 has a substantially blunt profile. Also, the housing 32 can be sized to open/support the vessel as it passes through it. Additionally, the housing 32 can include angled sidewalls sized to just be spaced just off the inner surface of the introducer sheath 10.


The housing 32 and protective coil 35 form a distal retaining member that maintains the position of the occluding device 100 on the flexible guidewire assembly 20 and helps to hold the occluding device 100 in a compressed state prior to its delivery and deployment within a vessel of the vasculature. The protective coil 35 extends from the housing 32 in the direction of the proximal end 23 of the delivery guidewire 21, as shown in FIG. 4. The protective coil 35 is secured to the housing 32 in any known manner. In a first embodiment, the protective coil 35 can be secured to the outer surface of the housing 32. In an alternative embodiment, the protective coil 35 can be secured within an opening of the housing 32 so that the housing 32 surrounds and internally receives the distal end 51 of the protective coil 35 (FIG. 4). As shown in FIGS. 3 and 4, the distal end 102 of the occluding device 100 is retained within the proximal end 52 so that the occluding device 100 cannot deploy while positioned in the sheath 10 or the micro-catheter 1.


At the proximal end of the occluding device 100, a bumper coil 60 and cap 62 prevent lateral movement of the occluding device 100 along the length of the guidewire 21 in the direction of the proximal end 23, see FIG. 3. The bumper coil 60 and cap 62 have an outer diameter D4 of about 0.018 inch to about 0.038 inch. In an embodiment, their outer diameter D4 is about 0.024 inch. The cap 62 contacts the proximal end 107 of the occluding device 100 and prevents it from moving along the length of the guidewire 21 away from the protective coil 35. The bumper coil 60 can be in the form of a spring that contacts and pressures the cap 62 in the direction of the protective coil 35, thereby creating a biasing force against the occluding device 100. This biasing force (pressure) aids in maintaining the secured, covered relationship between the distal end 102 of the occluding device 100 and the protective coil 35. As with any of the coils positioned along the delivery guidewire 21, the bumper coil 60 can be secured to the delivery guidewire 21 by soldering, welding, RF welding, glue, and/or other known adhesives.


In an alternative embodiment illustrated in FIG. 10, the bumper coil 60 is not utilized. Instead, a proximal end 107 of the occluding device 100 is held in position by a set of spring loaded arms (jaws) 140 while positioned within the introducer sheath 10 or the micro-catheter 1. The inner surfaces of the micro-catheter 1 and the introducer sheath 10 limit the radial expansion of the arms 140. When the proximal end of the occluding device passes out of the micro-catheter 1, the arms 140 would spring open and release the occluding device as shown in FIG. 11.


In another example, the occluding device 100 in the introducer sheath 10 or the micro-catheter 1 may expand within a vessel under pressure. FIG. 12 illustrates an example of an expanded occluding device 100 that expands responsive to pressure. Pressure may be applied through the micro-catheter 1 or the introducer sheath 10 as the occluding device 100 passes out of the micro-catheter 1. The pressure may be exerted through application of air, fluid, or any material for increasing the internal pressure of the occluding device. The increase in pressure within the occluding device 100 when the occluding device 100 passes out of the micro-catheter 1 may cause the occluding device to expand within the vessel. Conversely, a negative pressure may be exerted at the occluding device 100. FIG. 13 illustrates the occluding device 100 of FIG. 12 after a negative pressure is applied to the occluding device 100. The negative pressure may be applied via the micro-catheter 1 or the introducer sheath 10 and may cause the occluding device 100 to retract or decrease in size. In one example, a negative pressure is exerted at the occluding device 100 after the occluding device 100 is passed out of the micro-catheter 1 and expanded in the vessel. The negative pressure causes the occluding device 100 to retract. Upon retraction, the occluding device 100 may be reduced in size. In another example, the occluding device 100 may be replaced back into the microcatheter 1 after retraction. The negative pressure may be applied in a variety of ways. For example, the negative pressure may be applied by suction of air from the micro-catheter 1 or by removal or suction of fluid from the micro-catheter 1.


Also, in another example, the occluding device 100 may be expanded, for example, by application of increased pressure within the occluding device. The increased pressure may be administered via the delivery device by, for example, injecting air or fluid via the delivery device to the occluding device 100. The occluding device 100 may thus be expanded in a vessel such that the occluding device 100 may come into contact with the internal aspect of the wall of the vessel. In this way, at least a portion of the occluding device 100, while in the expanded state, may contact the wall of the vessel.


While in the expanded state, the occluding device 100 may be repositioned within the vessel. FIG. 18 illustrates an example of an expanded occluding device 100. FIG. 19 illustrates the example of FIG. 18 after the occluding device is repositioned within a blood vessel. In this example, the occluding device 100 may be expanded in a longitudinal axis along the vessel such that the occluding device 100 may move within the vessel while expanded. Pressure may be exerted by a user at a proximal end of the occluding device 100 such that the proximal end is moved distally within the vessel lumen. At the same time, frictional forces between the wall of the vessel and the more distal portions of the occluding device may prevent immediate movement of the more distal portions of the occluding device. When the pressure or force exerted at the proximal end exceeds a threshold level, the force may be transmitted to the more distal portions of the occluding device to cause the more distal portions of the occluding device to more distally in the lumen of the vessel. In this way, the occluding device may move distally in the vessel lumen and may be repositioned at a desired location within the vessel by the user. FIG. 19 illustrates distal repositioning of the occluding device in a blood vessel.


Similarly, the occluding device may be repositioned more proximally in the vessel lumen by the user. For example, the user may provide a force or pressure at a distal portion of the occluding device in a proximal direction. The distal portion of the occluding device may move proximally while frictional forces between the more proximal portions of the occluding device prevent initial movement of the more proximal portions of the occluding device. Hence, in this example, the occluding device compresses at a portion intermediate between the distal portion and the more proximal portions of the occluding device. When the pressure or force exerted by the user at the distal portion of the occluding device exceeds a threshold level that exceeds the frictional force preventing movement of the more proximal portions of the occluding device, the more proximal portions of the occluding device may move in a proximal direction responsive to the applied pressure or force. In this way, the occluding device may be repositioned proximally in the vessel.


In another example, the occluding device 100 may be repositioned in a blood vessel while the occluding device 100 is in a retracted state. FIG. 20 illustrates an example of the occluding device 100 in a retracted state. For example, negative pressure may be exerted at the occluding device 100 of FIG. 12 to cause the occluding device 100 to decrease in size as illustrated in FIG. 20. The occluding device 100 as illustrated in FIG. 20 is retracted and approximates the delivery device. FIG. 21 illustrates an example of repositioning the occluding device 100 while the occluding device is retracted. As FIG. 21 illustrates, the occluding device is moved in a distal direction. Similarly, the occluding device may also be repositioned in a proximal direction (not shown).


Also, deployment of the occluding device may be performed in parts. For example, the occluding device 100 may have a distal end and a proximal end. Deployment of the occluding device may include release of a distal end followed by release of the proximal end of the occluding device. Alternatively, deployment of the occluding device may include release of the proximal end followed by release of the distal end. Also, deployment of the occluding device may include release of the proximal end and the distal end of the occluding device 100 at approximately the same time.



FIG. 14 illustrates an example of release of the distal end of the occluding device 100 while the proximal end of the occluding device remains attached to the delivery device. As FIG. 14 shows, the distal end of the occluding device 100 is deployed and abuts the wall of the blood vessel. The proximal end of the occluding device 100 is still attached to the delivery device. Release of the proximal end of the occluding device may be accomplished in a variety of ways as described herein.


In addition, the partially deployed occluding device 100 as illustrated in FIG. 14 may be repositioned in the blood vessel. FIG. 15 illustrates an example of a partially deployed occluding device 100 in which the distal end of the occluding device 100 has been released from the delivery device while the proximal end of the delivery device 100 remains attached and non-deployed to the delivery device. In addition, FIG. 15 demonstrates repositioning of the occluding device while partially deployed. As FIG. 15 shows, the delivery device and occluding device 100 has been moved proximally in the blood vessel. Also, FIG. 15 illustrates that the occluding device is partially deployed in the blood vessel such that the distal end of the occluding device is released from the delivery device while the proximal end of the occluding device 100 remains attached to the delivery device.


Alternatively, the proximal end of the occluding device may be released from the delivery device while the distal end of the occluding device remains attached to the delivery device. The distal end of the occluding device may then be deployed or released from the delivery device at a subsequent time. FIG. 16 illustrates an example of a partially deployed occluding device 100 in a blood vessel in which the proximal end of the occluding device 100 is released from the delivery device while the distal end of the occluding device remains attached to the delivery device. The proximal end of the occluding device 100 thus approximates the walls of the blood vessel.



FIG. 17 illustrates the example of FIG. 16 in which the occluding device 100 is repositioned proximally in the blood vessel. In this example, the occluding device is partially deployed such that the proximal end of the occluding device 100 is released from the delivery device while the distal end of the occluding device 100 is attached. The occluding device is then moved or repositioned to a more proximal location within the blood vessel. Alternatively, the occluding device may also be moved or repositioned to a more distal location within the blood vessel (not shown).


In an alternative embodiment, the bumper coil 60 and cap 62 can be eliminated and the proximal end of the occluding device 100 can be held in position relative to the protective coil 35 by a tapered section of the guidewire 21. In such an embodiment, the enlarged cross section of this tapered section can be used to retain the occluding device 100 in position along the length of the delivery guidewire 21 and prevent movement of the occluding device 100 in the direction of the proximal end 23.


As shown in FIG. 4, the guidewire assembly 20 includes a support 70 for the occluding device 100. In a first embodiment, the support 70 can include an outer surface of the delivery guidewire 21 that is sized to contact the inner surface of the occluding device 100 when the occluding device 100 is loaded on the guidewire assembly 20. In this embodiment, the outer surface of the delivery guidewire 21 supports the occluding device 100 and maintains it in a ready to deploy state. In another embodiment, illustrated in the figures, the support 70 comprises a mid-coil 70 that extends from a location proximate the protective coil 35 rearward toward the bumper coil 60. The mid-coil 70 extends under the occluding device 100 and over the delivery guidewire 21, as shown in FIG. 1. The mid-coil 70 can be coextensive with one or more sections of the delivery guidewire 21. For example, the mid-coil 70 could be coextensive with only the second section 24 of the delivery guidewire 21 or it could extend along portions of both the third section 26 and the second section 24 of the delivery guidewire 21.


The mid-coil 70 provides the guidewire assembly 20 with an outwardly extending surface that is sized to contact the inner surface of the occluding device 100 in order to assist in supporting the occluding device and maintaining the occluding device 100 in a ready to deploy state. Like the other coils discussed herein and illustrated in the figures, the coiled form of the mid-coil 70 permits the mid-coil 70 to flex with the delivery guidewire 21 as the delivery guidewire 21 is advanced through the vasculature of the patient. The mid-coil 70 provides a constant diameter along a length of the delivery guidewire 21 that is covered by the occluding device 100 regardless of the taper of the delivery guidewire 21 beneath the occluding device 100. The mid-coil 70 permits the delivery guidewire 21 to be tapered so it can achieve the needed flexibility to follow the path of the vasculature without compromising the support provided to the occluding device 100. The mid-coil 70 provides the occluding device 100 with constant support regardless of the taper of the delivery guidewire 21 prior to the occluding device 100 being deployed. The smallest diameter of the occluding device 100 when in its compressed state is also controlled by the size of the mid-coil 70. Additionally, the diameter of the mid-coil 70 can be chosen so that the proper spacing, including no spacing, is established between the occluding device 100 and the inner wall of the micro-catheter 1 prior to deployment of the occluding device 100. The mid-coil 70 can also be used to bias the occluding device 100 away from the delivery guidewire 21 during its deployment.


In either embodiment, the support 70 can have an outer diameter D3 of about 0.010 inch to about 0.018 inch. In an embodiment, the outer diameter D3 is about 0.014 inch. The support 70 can also have a length L3 of about 2.0 cm to about 30 cm. In an embodiment, the length L3 of the support 70 is about 7 cm.


The occluding device 100 may also be placed on the mid-coil 70 between an optional pair of radio-opaque marker bands located along the length of the guidewire assembly 20. Alternatively, the protective coil 35, bumper coil 60 and or mid-coil 70 can include radio-opaque markers. In an alternative embodiment, the guidewire assembly 20 may include only a single radio-opaque marker. The use of radio-opaque markers allows for the visualization of the guidewire assembly 20 and the occluding device 100 during placement within the vasculature. Such visualization techniques may include conventional methods such as fluoroscopy, radiography, ultra-sonography, magnetic resonance imaging, etc.


The occluding device 100 can be delivered and deployed at the site of an aneurysm according to the following method and variations thereof. The delivery of the occluding device 100 includes introducing the micro-catheter 1 into the vasculature until it reaches a site that requires treatment. The micro-catheter 1 is introduced into the vasculature using a conventional technique such as being advanced over or simultaneously with a conventional vascular guidewire (not shown). The positioning of the micro-catheter 1 can occur before it receives the guidewire assembly 20 or while it contains the guidewire assembly 20. The position of the micro-catheter 1 within the vasculature can be determined by identifying radio-opaque markers positioned on or in the micro-catheter 1.


After the micro-catheter 1 is positioned at the desired location, the guidewire is removed and the distal end of the introducer sheath 10 is inserted into the proximal end of the micro-catheter 1, as shown in FIG. 1. In an embodiment, the distal end of the introducer sheath 10 is introduced through the hub 2 at the proximal end of the micro-catheter 1. The introducer sheath 10 is advanced within the micro-catheter 1 until a distal tip of the introducer sheath 10 is wedged within the micro-catheter 1. At this position, the introducer sheath 10 cannot be advanced further within the micro-catheter 1. The introducer sheath 10 is then securely held while the delivery guidewire assembly 20 carrying the occluding device 100 is advanced through the introducer sheath 10 until the occluding device 100 is advanced out of the introducer sheath 10 and into the micro-catheter 1.


The guidewire assembly 20 and the occluding device 100 are advanced through the micro-catheter 1 until the tip coil 29 is proximate the distal end of the micro-catheter 1. At this point, the position of the micro-catheter 1 and guidewire assembly 20 can be confirmed. The guidewire assembly 20 is then advanced out of the micro-catheter 1 and into the vasculature of the patient so that the proximal end 107 of the occluding device 100 is positioned outside the distal end of the micro-catheter 1 and adjacent the area to be treated. At any point during these steps, the position of the occluding device 100 can be checked to determine that it will be deployed correctly and at the desired location. This can be accomplished by using the radio-opaque markers discussed above.


When the distal end 102 of the occluding device 100 is positioned outside the micro-catheter 1, the proximal end 107 will begin to expand, in the direction of the arrows shown in FIG. 7, within the vasculature while the distal end 102 remains covered by the protective coil 35. When the occluding device 100 is in the proper position, the delivery guidewire 21 is rotated (See FIG. 8) until the distal end 102 of the occluding device 100 moves away from the protective coil 35 and expands within the vasculature at the desired location. The delivery guidewire 21 can be rotated either clockwise or counter clockwise as needed to deploy the occluding device 100. In an embodiment, the delivery guidewire 21 may be rotated, for example, between two and ten turns in either or both directions. In another example, the occluding device may be deployed by rotating the delivery guidewire 21 clockwise for less than five turns, for example, three to five turns. After the occluding device 100 has been deployed, the delivery guidewire 21 can be retracted into the micro-catheter 100 and removed form the body.


In one alternative or additional deployment method, the distal end 102 of the occluding device 100 may be passed outside of the micro-catheter 1. The occluding device 100 may be further advanced so that the proximal end 107 of the occluding device 100 passes outside of the micro-catheter. However, in this example, the proximal end 107 of the occluding device 100 expands responsive to the application of pressure to the inner surfaces of the occluding device 100. The applied pressure may be from any source. Examples of pressure exerted in the occluding device 100 include, but are not limited to, infusion of fluid or air into the lumen of the occluding device.


The increase in pressure in the occluding device may cause the occluding device 100 to expand. Expansion of the occluding device 100 may cause a disconnection of the proximal end 107 of the occluding device 100 and/or the distal end 102 of the occluding device 100 such that the occluding device may substantially fill the lumen of the vessel. Alternatively, the increase in pressure in the occluding device may expand the occluding device 100 without detachment of either the proximal end 107 or the distal end 102 of the occluding device 100. In this example, the occluding device 100 may be expanded without detaching the occluding device 100 from the delivery system. The expanded occluding device 100 may be adjusted and moved within the vessel in the expanded state while connected to the delivery system. When the occluding device 100 is at a desired location in the vessel, the occluding device 100 may be released from the delivery system. Release of the occluding device 100 from the delivery system may be accomplished in a variety of ways as described herein.


In addition, the coverage of the occluding device 100 may be adjusted while the occluding device is expanded and connected to the delivery system. For example, the occluding device 100 may be unsheathed from the micro-catheter 1 and expanded under pressure (e.g., from fluid or air) such that the occluding device 100 is expanded in the vessel. The position of the occluding device 100 may be further adjusted. Also, the pressure applied within the occluding device 100 may be adjusted to increase the size of the expanded occluding device 100 in the vessel. Relative adjustments of the size of the expanded occluding device 100 (i.e., by adjusting the amount of pressure applied to the occluding device 100) and of the position or location of the occluding device 100 permit control of coverage of the occluding device when placed in the vessel.


Also, a negative pressure may be applied (e.g., air suction or removal of fluid from within the occluding device 100) to cause the occluding device to retract. The retracted occluding device 100 may further be placed back into the micro-catheter 1. In one example, the occluding device 100 may be expanded and retracted as desired for movement or placement of the occluding device 100 within the vessel.


In an alternative or additional deployment step shown in FIG. 9, friction between the occluding device 100 and inner surface of the micro-catheter 1 cause the distal end of the occluding device 100 to separate from the protective coil 35. The friction can be created by the opening of the occluding device 100 and/or the mid-coil 70 biasing the occluding device 100 toward the inner surface of the micro-catheter 1. The friction between the micro-catheter 1 and the occluding device 100 will assist in the deployment of the occluding device 100. In those instances when the occluding device 100 does not open and separate from the protective coil 35 during deployment, the friction between occluding device 100 and the inner surface of the micro-catheter 1 will cause the occluding device 100 to move away from the protective coil 35 as the delivery guidewire 21 and the micro-catheter 1 move relative to each other. The delivery guidewire 21 can then be rotated and the occluding device 100 deployed within the vessel.


After the occluding device 100 radially self-expands into gentle, but secure, contact with the walls of the vessel so as to occlude the neck of the aneurysm A, the micro-catheter 1 may be removed entirely from the body of the patient. Alternatively, the micro-catheter 1 may be left in position within vasculature to allow for the insertion of additional tools or the application of drugs near the treatment site.


Known materials can be used in the present invention. One common material that can be used with the occluding device 100 and the guidewire 21 is Nitinol, a nickel-titanium shape memory alloy, which can be formed and annealed, deformed at a low temperature, and recalled to its original shape with heating, such as when deployed at body temperature in the body. The radio-opaque markers can be formed of radio-opaque materials including metals, such as platinum, or doped plastics including bismuth or tungsten to aid in visualization.


The apparatus and methods discussed herein are not limited to the deployment and use within the vascular system but may include any number of further treatment applications. Other treatment sites may include areas or regions of the body such as organ bodies. Modification of each of the above-described apparatus and methods for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the art are intended to be within the scope of the claims. Furthermore, no element, component or method step is intended to be dedicated to the public regardless of whether the element, component or method step is explicitly recited in the claims.

Claims
  • 1. A system for delivering a self-expanding device in a vessel, the system comprising: a delivery assembly comprising an elongate member and a retaining member, the retaining member positioned at a distal portion of the delivery assembly, the elongate member extending through a lumen of the retaining member, the lumen receiving an end of the self-expanding device such that the device end is radially disposed between the elongate member and the retaining member; anda catheter configured to radially expand or radially collapse at least a portion of the self-expanding device by applying a pressure against an internal portion of the self-expanding device;wherein the retaining member is rotatable relative to the self-expanding device, and wherein rotation of the retaining member moves the device end proximally relative to the retaining member, such that the device end is released from within the lumen.
  • 2. The system of claim 1, wherein the catheter is configured to radially retract the at least a portion of the self-expanding device by applying a negative pressure against the internal portion of the self-expanding device.
  • 3. The system of claim 1, wherein the retaining member comprises a protective coil and the self-expanding device is received within an interior of the protective coil.
  • 4. The system of claim 1, wherein the end of the self-expanding device is biased radially outwardly against an internal surface of the retaining member.
  • 5. The system of claim 1, wherein the catheter is removable, prior to applying the rotation, while the end of the self-expanding device remains within the retaining member.
  • 6. The system of claim 1, further comprising a support extending along and surrounding a portion of the elongate member and having an outer surface configured to engage an inner surface of the self-expanding device.
  • 7. The system of claim 1, further comprising a biasing member proximal to the self-expanding device that urges the self-expanding device toward the distal portion of the elongate member when the self-expanding device is positioned on the biasing member.
  • 8. The system of claim 1, further comprising an introducer sheath having a distal end for insertion into a proximal end of the catheter.
  • 9. The system of claim 1, wherein the self-expanding device comprises a stent.
  • 10. A system for delivering a self-expanding device in a vessel, the system comprising: a delivery assembly comprising an elongate member and a retaining member, the retaining member positioned at a distal portion of the delivery assembly, the elongate member extending through a lumen of the retaining member, the lumen receiving a distal portion of the self-expanding device, the device being concentrically constrained within the retaining member lumen and configured to radially expand against an internal surface of the retaining member; anda catheter configured to radially expand or radially collapse at least a portion of the self-expanding device by applying a pressure against an internal portion of the self-expanding device;wherein the retaining member is rotatable relative to the self-expanding device, and wherein rotation of the retaining member moves the device end proximally relative to the retaining member, such that the device end is released from within the lumen.
  • 11. The system of claim 10, wherein the catheter is configured to radially retract the at least a portion of the self-expanding device by applying a negative pressure against the internal portion of the self-expanding device.
  • 12. The system of claim 10, wherein the retaining member comprises a protective coil and the self-expanding device is received within an interior of the protective coil.
  • 13. The system of claim 10, wherein the catheter is removable, prior to applying the rotation, while the end of the self-expanding device remains within the retaining member.
  • 14. The system of claim 10, further comprising a support extending along and surrounding a portion of the elongate member and having an outer surface configured to engage an inner surface of the self-expanding device.
  • 15. The system of claim 10, further comprising a biasing member proximal to the self-expanding device that urges the self-expanding device toward the distal portion of the elongate member when the self-expanding device is positioned on the biasing member.
  • 16. The system of claim 10, further comprising an introducer sheath having a distal end for insertion into a proximal end of the catheter.
  • 17. The system of claim 10, wherein the self-expanding device comprises a stent.
Parent Case Info

This application is a continuation of U.S. application Ser. No. 13/596,240, filed Aug. 28, 2012, which is a continuation of U.S. application Ser. No. 11/420,023, filed May 24, 2006, now U.S. Pat. No. 8,267,985, which is a continuation-in-part of and claims priority to U.S. application Ser. No. 11/136,398, filed May 25, 2005, now U.S. Pat. No. 8,147,534, each of the above applications being expressly incorporated herein by reference in its entirety.

US Referenced Citations (612)
Number Name Date Kind
2790180 Hauser Apr 1957 A
4321711 Mano Mar 1982 A
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4538622 Samson et al. Sep 1985 A
4580568 Gianturco Apr 1986 A
4655771 Wallsten Apr 1987 A
4733665 Palmaz Mar 1988 A
4768507 Fischell et al. Sep 1988 A
4776337 Palmaz Oct 1988 A
4950227 Savin Aug 1990 A
4954126 Wallsten et al. Sep 1990 A
4998539 Delsanti Mar 1991 A
5011488 Ginsburg Apr 1991 A
5026377 Burton et al. Jun 1991 A
5035706 Giantureo et al. Jul 1991 A
5061275 Wallsten et al. Oct 1991 A
5064435 Porter Nov 1991 A
5108416 Ryan Apr 1992 A
5147370 McNamara Sep 1992 A
5160341 Brenneman et al. Nov 1992 A
5180368 Garrison Jan 1993 A
5192297 Hull Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5209731 Sterman et al. May 1993 A
5222971 Willard et al. Jun 1993 A
5242399 Lau et al. Sep 1993 A
5246420 Kraus et al. Sep 1993 A
5246445 Yachia et al. Sep 1993 A
5334210 Gianturco Aug 1994 A
5344426 Lau et al. Sep 1994 A
5360443 Barone et al. Nov 1994 A
5378239 Termin et al. Jan 1995 A
5382259 Phelps et al. Jan 1995 A
5401257 Chevalier, Jr. et al. Mar 1995 A
5405380 Gianotti et al. Apr 1995 A
5415637 Khosravi May 1995 A
5421826 Crocker et al. Jun 1995 A
5423849 Engelson et al. Jun 1995 A
5445646 Euteneuer et al. Aug 1995 A
5449372 Schmaltz et al. Sep 1995 A
5458615 Klemm et al. Oct 1995 A
5476505 Limon Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484444 Braunschweiler et al. Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5503636 Schmitt et al. Apr 1996 A
5507768 Lau et al. Apr 1996 A
5522822 Phelps et al. Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5549635 Solar Aug 1996 A
5562641 Flomenblit et al. Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5591225 Okuda Jan 1997 A
5599291 Balbierz et al. Feb 1997 A
5607466 Imbert et al. Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5626602 Gianotti et al. May 1997 A
5628783 Quiachon et al. May 1997 A
5632772 Alcime et al. May 1997 A
5636641 Fariabi Jun 1997 A
5643278 Wijay Jul 1997 A
5662703 Yurek et al. Sep 1997 A
5667522 Flomenblit et al. Sep 1997 A
5674276 Andersen et al. Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690120 Jacobsen et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5695499 Helgerson et al. Dec 1997 A
5700269 Pinchuk et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5709702 Cogita Jan 1998 A
5709703 Lukic et al. Jan 1998 A
5725552 Kotula et al. Mar 1998 A
5725570 Heath Mar 1998 A
5725571 Imbert et al. Mar 1998 A
5733294 Forber et al. Mar 1998 A
5733327 Igaki et al. Mar 1998 A
5735859 Fischell et al. Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5741333 Frid Apr 1998 A
5749883 Halpern May 1998 A
5749891 Ken et al. May 1998 A
5749919 Blanc May 1998 A
5749920 Quiachon et al. May 1998 A
5769884 Solovay Jun 1998 A
5769885 Quiachon et al. Jun 1998 A
5776099 Tremulis Jul 1998 A
5776140 Cottone Jul 1998 A
5776141 Klein et al. Jul 1998 A
5776142 Gunderson Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5797952 Klein Aug 1998 A
5800518 Piplani et al. Sep 1998 A
5807398 Shaknovich Sep 1998 A
5810837 Hofmann et al. Sep 1998 A
5814062 Sepetka et al. Sep 1998 A
5817102 Johnson et al. Oct 1998 A
5824039 Piplani et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824044 Quiachon et al. Oct 1998 A
5824058 Ravenscroft et al. Oct 1998 A
5833632 Jacobsen et al. Nov 1998 A
5836868 Ressemann et al. Nov 1998 A
5846261 Kotula et al. Dec 1998 A
5868754 Levine et al. Feb 1999 A
5873907 Frantzen Feb 1999 A
5888201 Stinson et al. Mar 1999 A
5902266 Leone et al. May 1999 A
5906640 Penn et al. May 1999 A
5911717 Jacobsen et al. Jun 1999 A
5916194 Jacobsen et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919204 Lukic et al. Jul 1999 A
5925060 Forber Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935148 Villar et al. Aug 1999 A
5944726 Blaeser et al. Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5951599 McCrory Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5957974 Thompson et al. Sep 1999 A
5964797 Ho Oct 1999 A
5972015 Scribner et al. Oct 1999 A
5980530 Willard Nov 1999 A
5980533 Holman Nov 1999 A
5980554 Lenker et al. Nov 1999 A
5984929 Bashiri et al. Nov 1999 A
6014919 Jacobsen et al. Jan 2000 A
6015432 Rakos et al. Jan 2000 A
6017319 Jacobsen et al. Jan 2000 A
6019778 Wilson et al. Feb 2000 A
6019786 Thompson Feb 2000 A
6022369 Jacobsen et al. Feb 2000 A
6024754 Engelson Feb 2000 A
6024763 Lenker et al. Feb 2000 A
6027516 Kolobow et al. Feb 2000 A
6033423 Ken et al. Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6051021 Frid Apr 2000 A
6056993 Leidner et al. May 2000 A
6063070 Eder May 2000 A
6063104 Villar et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6068634 Lorentzen et al. May 2000 A
6074407 Levine et al. Jun 2000 A
6077295 Limon et al. Jun 2000 A
6086577 Ken et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096052 Callister et al. Aug 2000 A
6102942 Ahari Aug 2000 A
6113607 Lau Sep 2000 A
6123712 Di Caprio et al. Sep 2000 A
6123715 Amplatz Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6132459 Piplani et al. Oct 2000 A
6139543 Esch et al. Oct 2000 A
6139564 Teoh Oct 2000 A
6146415 Fitz Nov 2000 A
6149680 Shelso et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6165178 Bashiri et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6168618 Frantzen Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6183410 Jacobsen et al. Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6197046 Piplani et al. Mar 2001 B1
6206868 Parodi Mar 2001 B1
6210400 Hebert et al. Apr 2001 B1
6210434 Quiachon et al. Apr 2001 B1
6210435 Piplani et al. Apr 2001 B1
6214038 Piplani et al. Apr 2001 B1
6214042 Jacobsen et al. Apr 2001 B1
6221086 Forber Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6224609 Ressemann et al. May 2001 B1
6224829 Piplani et al. May 2001 B1
6231597 Deem et al. May 2001 B1
6235050 Quiachon et al. May 2001 B1
6241758 Cox Jun 2001 B1
6241759 Piplani et al. Jun 2001 B1
6245103 Stinson Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6260458 Jacobsen et al. Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6264671 Stack et al. Jul 2001 B1
6270523 Herweck et al. Aug 2001 B1
6280465 Cryer Aug 2001 B1
6287331 Heath Sep 2001 B1
6290721 Heath Sep 2001 B1
6302810 Yokota Oct 2001 B2
6302893 Limon et al. Oct 2001 B1
6322576 Wallace et al. Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6322587 Quiachon et al. Nov 2001 B1
6331184 Abrams Dec 2001 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6346117 Greenhalgh Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350199 Williams et al. Feb 2002 B1
6350270 Roue Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6355061 Quiachon et al. Mar 2002 B1
6368339 Amplatz Apr 2002 B1
6368344 Fitz Apr 2002 B1
6368557 Piplani et al. Apr 2002 B1
6371928 Mcfann et al. Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6375676 Cox Apr 2002 B1
6379618 Piplani et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6383174 Eder May 2002 B1
6387118 Hanson May 2002 B1
6391037 Greenhalgh May 2002 B1
6395017 Dwyer et al. May 2002 B1
6395022 Piplani et al. May 2002 B1
6398802 Yee Jun 2002 B1
6409683 Fonseca et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6416536 Yee Jul 2002 B1
6428489 Jacobsen et al. Aug 2002 B1
6428558 Jones et al. Aug 2002 B1
6432130 Hanson Aug 2002 B1
6440088 Jacobsen et al. Aug 2002 B1
6443971 Boylan et al. Sep 2002 B1
6443979 Stalker et al. Sep 2002 B1
6447531 Amplatz Sep 2002 B1
6451025 Jervis Sep 2002 B1
6454780 Wallace Sep 2002 B1
6454999 Farhangnia et al. Sep 2002 B1
6468266 Bashiri et al. Oct 2002 B1
6478778 Jacobsen et al. Nov 2002 B1
6482221 Hebert et al. Nov 2002 B1
6491648 Cornish et al. Dec 2002 B1
6503450 Afzal et al. Jan 2003 B1
6506204 Mazzocchi Jan 2003 B2
6511468 Cragg et al. Jan 2003 B1
6514261 Randall et al. Feb 2003 B1
6520983 Colgan et al. Feb 2003 B1
6524299 Tran et al. Feb 2003 B1
6527763 Esch et al. Mar 2003 B2
6533811 Ryan et al. Mar 2003 B1
6540778 Quiachon et al. Apr 2003 B1
6547779 Levine et al. Apr 2003 B2
6547804 Porter et al. Apr 2003 B2
6551303 Van Tassel et al. Apr 2003 B1
6572646 Boylan et al. Jun 2003 B1
6576006 Limon et al. Jun 2003 B2
6579303 Amplatz Jun 2003 B2
6582460 Cryer Jun 2003 B1
6585748 Jeffree Jul 2003 B1
6589236 Wheelock et al. Jul 2003 B2
6589256 Forber Jul 2003 B2
6589265 Palmer et al. Jul 2003 B1
6589273 McDermott Jul 2003 B1
6592616 Stack et al. Jul 2003 B1
6599308 Amplatz Jul 2003 B2
6602280 Chobotov Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6605110 Harrison Aug 2003 B2
6605111 Bose et al. Aug 2003 B2
6607539 Hayashi et al. Aug 2003 B1
6607551 Sullivan et al. Aug 2003 B1
6613074 Mitelberg et al. Sep 2003 B1
6613075 Healy et al. Sep 2003 B1
6613078 Barone et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6626939 Burnside et al. Sep 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6638243 Kupiecki Oct 2003 B2
6645240 Yee Nov 2003 B2
6646218 Campbell et al. Nov 2003 B1
6652508 Griffin et al. Nov 2003 B2
6652556 VanTassel et al. Nov 2003 B1
6656212 Ravenscroft et al. Dec 2003 B2
6656218 Denardo et al. Dec 2003 B1
6660024 Flaherty et al. Dec 2003 B1
6663666 Quiachon et al. Dec 2003 B1
6666882 Bose et al. Dec 2003 B1
6669719 Wallace et al. Dec 2003 B2
6669721 Bose et al. Dec 2003 B1
6673089 Yassour et al. Jan 2004 B1
6673100 Diaz et al. Jan 2004 B2
6679893 Tran Jan 2004 B1
6682546 Amplatz Jan 2004 B2
6682557 Quiachon et al. Jan 2004 B1
6685735 Ahari Feb 2004 B1
6689162 Thompson Feb 2004 B1
6689486 Ho et al. Feb 2004 B2
6699274 Stinson Mar 2004 B2
6702843 Brown et al. Mar 2004 B1
6709454 Cox et al. Mar 2004 B1
6712834 Yassour et al. Mar 2004 B2
6716238 Elliott Apr 2004 B2
6726700 Levine Apr 2004 B1
6730108 Van Tassel et al. May 2004 B2
6733519 Lashinski et al. May 2004 B2
6740105 Yodfat et al. May 2004 B2
6740112 Yodfat et al. May 2004 B2
6743219 Dwyer et al. Jun 2004 B1
6746468 Sepetka et al. Jun 2004 B1
6746890 Gupta et al. Jun 2004 B2
6755855 Yurek et al. Jun 2004 B2
6758885 Leffel et al. Jul 2004 B2
6767361 Quiachon et al. Jul 2004 B2
6773446 Dwyer et al. Aug 2004 B1
6780196 Chin et al. Aug 2004 B2
6793667 Hebert et al. Sep 2004 B2
6802851 Jones et al. Oct 2004 B2
6811560 Jones et al. Nov 2004 B2
6814748 Baker et al. Nov 2004 B1
6818006 Douk et al. Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6849084 Rabkin et al. Feb 2005 B2
6855153 Saadat Feb 2005 B2
6858034 Hijlkema et al. Feb 2005 B1
6860893 Wallace et al. Mar 2005 B2
6860898 Stack et al. Mar 2005 B2
6860901 Baker et al. Mar 2005 B1
6866677 Douk et al. Mar 2005 B2
6866680 Yassour et al. Mar 2005 B2
6887267 Dworschak et al. May 2005 B2
6890337 Feeser et al. May 2005 B2
6936055 Ken et al. Aug 2005 B1
6955685 Escamitla et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6964670 Shah et al. Nov 2005 B1
6976991 Hebert et al. Dec 2005 B2
6989024 Hebert et al. Jan 2006 B2
6994092 van der Burg et al. Feb 2006 B2
6994717 Konya et al. Feb 2006 B2
6994721 Israel Feb 2006 B2
7001422 Escamilla et al. Feb 2006 B2
7004964 Thompson et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7011675 Hemerick et al. Mar 2006 B2
7029487 Greene, Jr. et al. Apr 2006 B2
7037330 Rivelli, Jr. et al. May 2006 B1
7066951 Chobotov Jun 2006 B2
7069835 Nishri et al. Jul 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7083632 Avellanet et al. Aug 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7101392 Heath Sep 2006 B2
7107105 Bjorklund et al. Sep 2006 B2
7118539 Vrba et al. Oct 2006 B2
7118594 Quiachon et al. Oct 2006 B2
7122050 Randall et al. Oct 2006 B2
7125419 Sequin et al. Oct 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7128736 Abrams et al. Oct 2006 B1
7137990 Hebert et al. Nov 2006 B2
7166125 Baker et al. Jan 2007 B1
7169170 Widenhouse Jan 2007 B2
7169172 Levine et al. Jan 2007 B2
7169177 Obara Jan 2007 B2
7172617 Colgan et al. Feb 2007 B2
7195636 Avellanet et al. Mar 2007 B2
7195639 Quiachon et al. Mar 2007 B2
7195648 Jones et al. Mar 2007 B2
7201768 Diaz et al. Apr 2007 B2
7201769 Jones et al. Apr 2007 B2
7211109 Thompson May 2007 B2
7213495 McCullagh et al. May 2007 B2
7229461 Chin et al. Jun 2007 B2
7232461 Ramer Jun 2007 B2
7235096 Van Tassel et al. Jun 2007 B1
7264632 Wright et al. Sep 2007 B2
7275471 Nishri et al. Oct 2007 B2
7279005 Stinson Oct 2007 B2
7279208 Goffena et al. Oct 2007 B1
7294137 Riveili, Jr. et al. Nov 2007 B2
7294146 Chew et al. Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7300460 Levine et al. Nov 2007 B2
7306624 Yodfat et al. Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7311031 McCullagh et al. Dec 2007 B2
7320702 Hammersmark et al. Jan 2008 B2
7331973 Gesswein et al. Feb 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7331980 Dubrul et al. Feb 2008 B2
7331985 Thompson et al. Feb 2008 B2
7338518 Chobotov Mar 2008 B2
7419503 Pulnev et al. Sep 2008 B2
7468070 Henry et al. Dec 2008 B2
7470282 Shelso Dec 2008 B2
7473271 Gunderson Jan 2009 B2
7491224 Cox et al. Feb 2009 B2
RE40816 Taylor et al. Jun 2009 E
7578826 Gandhi et al. Aug 2009 B2
7597704 Frazier et al. Oct 2009 B2
7785361 Nikolchev et al. Aug 2010 B2
7862602 Licata et al. Jan 2011 B2
8114154 Righini et al. Feb 2012 B2
8147534 Berez et al. Apr 2012 B2
8192480 Tieu et al. Jun 2012 B2
8206431 Seppala et al. Jun 2012 B2
8236042 Berez et al. Aug 2012 B2
8257421 Berez et al. Sep 2012 B2
8267985 Garcia et al. Sep 2012 B2
8267986 Berez Sep 2012 B2
8273101 Garcia et al. Sep 2012 B2
8409267 Tran et al. Apr 2013 B2
8585748 Delap Nov 2013 B2
9050206 Tran et al. Jun 2015 B2
9155647 Liang et al. Oct 2015 B2
20010000797 Mazzocchi May 2001 A1
20010012949 Forber Aug 2001 A1
20010012961 Deem et al. Aug 2001 A1
20010049547 Moore Dec 2001 A1
20010053929 Vonesh Dec 2001 A1
20020013618 Marotta et al. Jan 2002 A1
20020062091 Jacobsen et al. May 2002 A1
20020078808 Jacobsen et al. Jun 2002 A1
20020087119 Parodi Jul 2002 A1
20020099405 Yurek et al. Jul 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020138133 Lenz et al. Sep 2002 A1
20020143384 Ozasa Oct 2002 A1
20020165572 Saadat Nov 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20020188341 Elliott Dec 2002 A1
20030028209 Teoh et al. Feb 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030069522 Jacobsen et al. Apr 2003 A1
20030100945 Yodfat et al. May 2003 A1
20030109887 Galdonik et al. Jun 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030149465 Heidner et al. Aug 2003 A1
20030163155 Haverkost et al. Aug 2003 A1
20030163156 Hebert et al. Aug 2003 A1
20030171739 Murphy et al. Sep 2003 A1
20030195553 Wallace et al. Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030208256 DiMatteo et al. Nov 2003 A1
20030216693 Mickley Nov 2003 A1
20040024416 Yodfat et al. Feb 2004 A1
20040044391 Porter Mar 2004 A1
20040044395 Nelson Mar 2004 A1
20040049204 Harari et al. Mar 2004 A1
20040049256 Yee Mar 2004 A1
20040059407 Escamilla et al. Mar 2004 A1
20040073300 Chouinard et al. Apr 2004 A1
20040078071 Escamilla et al. Apr 2004 A1
20040093010 Gesswein May 2004 A1
20040093063 Wright May 2004 A1
20040098028 Martinez et al. May 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040127912 Rabkin Jul 2004 A1
20040133223 Weber et al. Jul 2004 A1
20040138733 Weber et al. Jul 2004 A1
20040138737 Davidson et al. Jul 2004 A1
20040143286 Johnson et al. Jul 2004 A1
20040186368 Ramzipoor et al. Sep 2004 A1
20040186551 Kao Sep 2004 A1
20040186562 Cox Sep 2004 A1
20040193178 Nikolchev Sep 2004 A1
20040193179 Nikolchev Sep 2004 A1
20040193206 Gerberding et al. Sep 2004 A1
20040199243 Yodfat Oct 2004 A1
20040204749 Gunderson Oct 2004 A1
20040215332 Frid Oct 2004 A1
20040220585 Nikolchev Nov 2004 A1
20050010281 Yodfat et al. Jan 2005 A1
20050033408 Jones et al. Feb 2005 A1
20050033409 Burke et al. Feb 2005 A1
20050049668 Jones et al. Mar 2005 A1
20050049670 Jones et al. Mar 2005 A1
20050090890 Wu et al. Apr 2005 A1
20050096728 Ramer May 2005 A1
20050096732 Marotta et al. May 2005 A1
20050107823 Leone et al. May 2005 A1
20050131523 Bashiri et al. Jun 2005 A1
20050137680 Ortiz et al. Jun 2005 A1
20050209672 George et al. Sep 2005 A1
20050209674 Kutscher et al. Sep 2005 A1
20050228434 Amplatz et al. Oct 2005 A1
20050246010 Alexander et al. Nov 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050283220 Gobran et al. Dec 2005 A1
20050283222 Betelia et al. Dec 2005 A1
20050288764 Snow et al. Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060025845 Escamilla et al. Feb 2006 A1
20060036309 Hebert et al. Feb 2006 A1
20060041182 Forbes Feb 2006 A1
20060052815 Fitz et al. Mar 2006 A1
20060052816 Bates et al. Mar 2006 A1
20060058865 Case et al. Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060089703 Escamilla et al. Apr 2006 A1
20060095213 Escamilla et al. May 2006 A1
20060111771 Ton et al. May 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116714 Sepetka et al. Jun 2006 A1
20060116750 Hebert et al. Jun 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060167494 Suddaby Jul 2006 A1
20060184238 Kaufmann et al. Aug 2006 A1
20060190076 Taheri Aug 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060206201 Garcia et al. Sep 2006 A1
20060212127 Karabey et al. Sep 2006 A1
20060235464 Avellanet et al. Oct 2006 A1
20060235501 Igaki Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20070021816 Rudin et al. Jan 2007 A1
20070043419 Nikolchev et al. Feb 2007 A1
20070055339 George et al. Mar 2007 A1
20070055365 Greenberg et al. Mar 2007 A1
20070073379 Chang Mar 2007 A1
20070088387 Eskridge et al. Apr 2007 A1
20070100414 Licata et al. May 2007 A1
20070106311 Wallace et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070119295 McCullagh et al. May 2007 A1
20070123969 Gianotti May 2007 A1
20070162104 Frid Jul 2007 A1
20070167980 Figulla et al. Jul 2007 A1
20070173928 Morsi Jul 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070198076 Hebert et al. Aug 2007 A1
20070203559 Freudenthal et al. Aug 2007 A1
20070203563 Hebert et al. Aug 2007 A1
20070203567 Levy Aug 2007 A1
20070208376 Meng Sep 2007 A1
20070221230 Thompson et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070225794 Thramann et al. Sep 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20070288083 Hines Dec 2007 A1
20070299500 Hebert et al. Dec 2007 A1
20070299501 Hebert et al. Dec 2007 A1
20070299502 Hebert et al. Dec 2007 A1
20080003354 Nolan Jan 2008 A1
20080021535 Leopold et al. Jan 2008 A1
20080039933 Yodfat et al. Feb 2008 A1
20080082154 Tseng et al. Apr 2008 A1
20080097495 Feller, III et al. Apr 2008 A1
20080119886 Greenhalgh et al. May 2008 A1
20080154286 Abbott et al. Jun 2008 A1
20080195139 Donald et al. Aug 2008 A1
20080208320 Tan-Malecki et al. Aug 2008 A1
20080219533 Grigorescu Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080221666 Licata Sep 2008 A1
20080255654 Hebert et al. Oct 2008 A1
20080262590 Murray Oct 2008 A1
20080269774 Garcia et al. Oct 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080300667 Hebert et al. Dec 2008 A1
20080319533 Lehe Dec 2008 A1
20090024202 Dave et al. Jan 2009 A1
20090024205 Hebert et al. Jan 2009 A1
20090025820 Adams Jan 2009 A1
20090030496 Kaufmann et al. Jan 2009 A1
20090030497 Metcalf et al. Jan 2009 A1
20090082803 Adams et al. Mar 2009 A1
20090105802 Henry et al. Apr 2009 A1
20090105803 Shelso Apr 2009 A1
20090112251 Qian et al. Apr 2009 A1
20090125093 Hansen May 2009 A1
20090138065 Zhang et al. May 2009 A1
20090163986 Tieu et al. Jun 2009 A1
20090177288 Wallsten et al. Jul 2009 A1
20090192536 Berez et al. Jul 2009 A1
20090198318 Berez et al. Aug 2009 A1
20090210047 Amplatz et al. Aug 2009 A1
20090264978 Dieck et al. Oct 2009 A1
20090270974 Berez et al. Oct 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20090287241 Berez et al. Nov 2009 A1
20090287288 Berez et al. Nov 2009 A1
20090287292 Becking et al. Nov 2009 A1
20090292348 Berez et al. Nov 2009 A1
20090318947 Garcia et al. Dec 2009 A1
20090319017 Berez et al. Dec 2009 A1
20100030220 Truckai et al. Feb 2010 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100076317 Babic et al. Mar 2010 A1
20100152767 Greenhalgh et al. Jun 2010 A1
20100268204 Tieu et al. Oct 2010 A1
20100305606 Gandhi et al. Dec 2010 A1
20100331948 Turovskiy et al. Dec 2010 A1
20110040372 Hansen et al. Feb 2011 A1
20110313447 Strauss et al. Dec 2011 A1
20120041470 Shrivastava et al. Feb 2012 A1
20120041474 Eckhouse et al. Feb 2012 A1
20120065720 Strauss et al. Mar 2012 A1
20120221095 Berez et al. Aug 2012 A1
20120277784 Berez et al. Nov 2012 A1
20120283765 Berez et al. Nov 2012 A1
20120283815 Berez et al. Nov 2012 A1
20130131775 Hadley May 2013 A1
20130144380 Quadri et al. Jun 2013 A1
20130172925 Garcia et al. Jul 2013 A1
20130172976 Garcia et al. Jul 2013 A1
20140094896 Berez et al. Apr 2014 A1
Foreign Referenced Citations (58)
Number Date Country
101365401 Feb 2009 CN
102548504 Jul 2012 CN
418677 Mar 1991 EP
442657 Aug 1991 EP
442657 Aug 1991 EP
696447 Feb 1996 EP
1324720 Jul 2003 EP
1369098 Dec 2003 EP
1400219 Mar 2004 EP
1621148 Feb 2006 EP
2 143 404 Jan 2010 EP
2 143 460 Jan 2010 EP
10-328216 Dec 1998 JP
11-299901 Nov 1999 JP
2001-509412 Jul 2001 JP
2005-074230 Mar 2005 JP
WO-9509586 Apr 1995 WO
WO-9726939 Jul 1997 WO
WO-9809583 Mar 1998 WO
WO-9902092 Jan 1999 WO
WO-9903404 Jan 1999 WO
WO-9905977 Feb 1999 WO
WO-99049812 Dec 1999 WO
WO-9962432 Dec 1999 WO
0013593 Mar 2000 WO
WO-0013593 Mar 2000 WO
WO-2001005331 Jan 2001 WO
WO-0193782 Dec 2001 WO
WO-0200139 Jan 2002 WO
WO-0228320 Apr 2002 WO
WO-02056798 Jul 2002 WO
WO-0260345 Aug 2002 WO
WO-0271977 Sep 2002 WO
WO-03007840 Jan 2003 WO
03022124 Mar 2003 WO
WO-03022124 Mar 2003 WO
WO-2003049600 Oct 2003 WO
WO-2004010878 Feb 2004 WO
WO-2004030575 Apr 2004 WO
WO-2004066809 Aug 2004 WO
WO-2004087006 Nov 2004 WO
2005011527 Feb 2005 WO
WO-2005018728 Mar 2005 WO
WO-2005030093 Apr 2005 WO
WO-2005117718 Dec 2005 WO
WO-2006026744 Mar 2006 WO
WO-2006052322 May 2006 WO
WO-2006091891 Aug 2006 WO
2006127005 Nov 2006 WO
WO-2006127005 Nov 2006 WO
WO-2007121405 Oct 2007 WO
WO-2008022327 Feb 2008 WO
WO-2008157507 Dec 2008 WO
WO-2008151204 Dec 2008 WO
WO-2005115118 Jul 2009 WO
WO-2009134337 Nov 2009 WO
WO-2010030991 Mar 2010 WO
WO-2011130081 Oct 2011 WO
Non-Patent Literature Citations (33)
Entry
Vanninen , et al., “Broad Based Intracranial Aneurysmn: Thrombosis Induced by Stent Placement”, Am J Neuroradiol, 24, 2003, 263-266.
Qureshi, Adnan, Endovascular Treatment of Cerebrovascular Diseases and Intracranial Neoplasms, The Lancelet, Mar. 2004, vol. 363, pp. 804-813.
Steiger, Pathophysiology of Development and Rupture of Cerebral Aneurysms, Acta Nurochirurgica, Mar. 1990, vol. Supplementum 48, Pages in 62 pages.
Tenaglia, et al., Ultrasound Guide Wire-Directed Stent Deployment, Duke University Medical Center, Department of Medicine, 1993 USA.
Yu, et al., A Steady Flow Analysis on the Stented and Non-Stented Sidewall Aneurysm Models, Medical Engineering and Physics, Apr. 1999, Issue 21, pp. 133-141.
Hill, et al., “Initial Results of the AMPLATZER Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing” US Cardiology, 2004.
Ronen, “AMPLATZER Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007.
U.S. Appl. No. 14/879,749, filed Oct. 9, 2015.
U.S. Appl. No. 11/136,398, filed Apr. 3, 2012, U.S. Pat. No. 8,147,534.
U.S. Appl. No. 12/419,031, filed Sep. 4, 2012, U.S. Pat. No. 8,257,421.
U.S. Appl. No. 12/420,383, filed Aug. 7, 2012, U.S. Pat. No. 8,236,042.
U.S. Appl. No. 11/420,023, filed Sep. 18, 2012, U.S. Pat. No. 8,267,985.
U.S. Appl. No. 12/426,560, filed Sep. 25, 2012, U.S. Pat. No. 8,273,101.
U.S. Appl. No. 13/552,105, filed Jul. 18, 2012, U.S. Pat. No. 9,155,647.
U.S. Appl. No. 13/407,835, filed Feb. 29, 2012, U.S. Publication No. 2012/0221095.
U.S. Appl. No. 13/550,137, filed Jul. 16, 2012, U.S. Publication No. 2012/0283765.
U.S. Appl. No. 13/550,122, filed Jul. 16, 2012, U.S. Publication No. 2012/0277784.
U.S. Appl. No. 13/596,248, filed Aug. 28, 2012, U.S. Publication No. 2013/0172925.
U.S. Appl. No. 13/550,095, filed Jul. 16, 2012, U.S. Publication No. 2012/0283815.
U.S. Appl. No. 13/596,240, filed Aug. 28, 2012, U.S. Publication No. 2013/0172976.
U.S. Appl. No. 12/412,731, filed Mar. 27, 2009, U.S. Publication No. 2009/0264978.
U.S. Appl. No. 12/465,475, filed May 13, 2009, U.S. Publication No. 2009/0287292.
U.S. Appl. No. 14/879,749, filed Oct. 9, 2015, Not Yet Published.
Benndorf, et al. Treatment of a Ruptured Dissecting Vertebral Artery Aneurysm with Double Stent Placement: Case Report ANJR Am J Neuroradiol, Nov.-Dec. 2001, vol. 22, pp. 1844-1848.
Brilstra, et al., Treatment of Intracranial Aneurysms by Embolization with Coils: A Systematic Review, Stroke, Journal of the American Heart Association, 1999, vol. 30, pp. 470-476.
Ferguson, Gary, Physical Factors in the Initiation, Growth and Rupture of Human Intracranial Saccular Ameurysms, J. Neurosurg, Dec. 1972, vol. 37, pp. 666-667.
Geremia, et al., Embolization of Experimentally Created Aneurysms with Intravascular Stent Devices, ANJR American Journal of Neuroradiology, Aug. 1994, vol. 15, pp. 1223-1231.
Geremia, et al., Occlusion of Experimentally Created Fusiform Aneurysms with Porous Metallic Stents, ANJR Am J Neuroradiol, Apr. 2000, Issue 21, pp. 739-745.
Lanzino, et al., Efficacy and Current Limitations of Intravascular Stents for Intracranial Internal Carotid, Vertebral, and Basilar Artery Aneurysms, Journal of Neurosurgery, Oct. 1999, vol. 91, Issue 4, pp. 538-546.
Lieber, et al., Alteration of Hemodynamics in Aneurysm Models by Stenting: Influence of Stent Porosity, Ann of Biomedical Eng., 1997, vol. 25, pp. 460-469, Buffalo, NY.
Lieber, et al., The Physics of Endoluminal Stenting in the Treatment of Cerebrovascular Aneurysms, Neurological Research, 2002, Vcol 24, Issue Supplement 1, pp. S32-S42.
Moss, et al., Vascular Occlusion with a Balloon-Expadable Stent Occluder, Radiology, May 1994, vol. 191, Issue 2, pp. 483-486.
Pereira, Edgard, History of Endovascular Aneurysm Occlusion, Management of Cerebral Aneurysms, 2004, pp. 11-26.
Related Publications (1)
Number Date Country
20160151184 A1 Jun 2016 US
Continuations (2)
Number Date Country
Parent 13596240 Aug 2012 US
Child 14953986 US
Parent 11420023 May 2006 US
Child 13596240 US
Continuation in Parts (1)
Number Date Country
Parent 11136398 May 2005 US
Child 11420023 US